LUSEFI, an oral anti-diabetic for type 2 diabetes mellitus which has just been launched by Taisho Pharmaceutical is expected to provide adequate glycaemic control, which lowers blood glucose and serves as a new alternative prescription.
It is an orally-active second generation sodium-glucose cotransporter 2 (SGLT2) inhibitor that is developed and produced by Taisho Pharmaceutical, Japan. Formulated with a new mechanism of action that selectively inhibits SGLT2 – this treatment lowers blood glucose levels by inhibiting the reabsorption of glucose in the renal tubule, thus increasing urinary glucose excretion and eventually reducing blood glucose levels. Suitable for type 2 diabetes mellitus patients aged 20 and above.
A clinical study on Lusefi that was conducted in Japan demonstrated improvement in the blood glucose level for monotherapy. At the end of the study, it was found that in addition to lowering and maintaining a healthy blood glucose level, the anti glycaemic effect of Lusefi also helped patients decrease their body weight. Throughout the study, Lusefi also demonstrated a good safety profile.
Lusefi, with its active ingredients of Luseoglifflozin Hydrate is available in 2.5mg and 5mg tablets via doctor’s prescription.
Taisho Pharmaceutical's mission is to contribute to public health and wellbeing. The company aims to address the diverse array of people's needs by providing a broad range of products in fields ranging from disease prevention to treatment.
“In recent years, the environment surrounding the pharmaceuticals industry has changed dramatically. While responding flexibly and swiftly to these changes, we too venture in new therapeutic areas, such as diabetes. We see the needs of patients, and we are now the new healthcare partner in Diabetes Management,’’ said Toru Tatezono, COO of Taisho Pharmaceutical Malaysia.
Dr Zanariah Hussein, Consultant Endocrinologist at Hospital Putrajaya, and Dr Chan Siew Pheng, Consultant Endocrinologist at the Subang Jaya Medical Centre were also present at the media launch event to discuss the rising prevalence of Type 2 Diabetes in Malaysia as well as the research that has been conducted in the field of diabetes.
Taisho Pharmaceuticals which is principally involved in the self-medication business achieved through over-the-counter medicines and health related products as well as prescription pharmaceuticals, is continuously looking to develop new, highly original medicines that are effective on a global scale. With the development of Lusefi, Taisho Pharmaceutical now expands its medical supplies business into diabetes, which is one of the biggest noncommunicable diseases – joining its other core business areas which include the central nervous system, immunology/allergy and infectious disease.
Taisho Pharmaceuticals through the acquisition of HOE Pharmaceuticals strengthens its position in Malaysia with a combined expertise in dermatological and cosmeceutical products as well as self-medication medicines and prescription pharmaceuticals.
About Taisho Pharmaceutical Holdings Co. Ltd.
Taisho Pharmaceutical Holdings Co. Ltd, one of the leading pharmaceutical companies in Japan acquired HOE Pharmaceuticals in 2011. With a philosophy of contributing to society by creating superior pharmaceuticals and products, Taisho Pharmaceutical Holdings practises the Japanese tradition of SHINSO, which employs high social ethics in all business matters. It is Taisho’s intension to adhere strictly to their philosophy and to strive to contribute to all fields of healthcare.
